Kyowa Kirin Co., Ltd. (4151.T) stock analysis

In our weekly check, Kyowa Kirin Co., Ltd. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 21 pass, warnings: 3, red flags: 1.

About Kyowa Kirin Co., Ltd.

Kyowa Kirin Co., Ltd. is a Healthcare company (Medical - Pharmaceuticals) based in Japan, listed on JPX as 4151.T.

What our checks show for 4151.T

Red flags

• Recovering from its deepest fall took about 5.4 years.

Warning signs

• Analysts expect only about 0.8% a year of growth in revenue.
• The price swings a lot: 37.8% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 56% from a peak. Would you have held through that?

Strengths

• Debt is low: 0.02x equity.
• Operating profit covers interest 39.9 times over.
• The gross margin is 73.9% and has risen by 1.8 points: pricing power is holding.
• Operating cash flow is 1.7x net profit: the profit arrives as real cash.
• Earnings per share grew 15.9% a year over the last 3 years.
• Net profit grew 14.9% a year over the last 3 years.

Next earnings report: 2026-11-02

Similar companies

RICHT.BD · 000250.KQ · SOBI.ST

Questions

What grade does Kyowa Kirin Co., Ltd. (4151.T) have?

In our weekly check, Kyowa Kirin Co., Ltd. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 21 pass, warnings: 3, red flags: 1. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 4151.T stock?

This week's biggest flags for Kyowa Kirin Co., Ltd.: Slow recovery after falls, Weak revenue forecast, Very volatile. In total 4 of 25 checks show a warning or a red flag.

What does Kyowa Kirin Co., Ltd. do?

Kyowa Kirin Co., Ltd. is a Healthcare company (Medical - Pharmaceuticals) based in Japan, listed on JPX as 4151.T.

When does Kyowa Kirin Co., Ltd. report earnings next?

The next earnings report is expected on 2026-11-02. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis